AU2019368654C1 - Heterocyclic kinase inhibitors and uses thereof - Google Patents

Heterocyclic kinase inhibitors and uses thereof Download PDF

Info

Publication number
AU2019368654C1
AU2019368654C1 AU2019368654A AU2019368654A AU2019368654C1 AU 2019368654 C1 AU2019368654 C1 AU 2019368654C1 AU 2019368654 A AU2019368654 A AU 2019368654A AU 2019368654 A AU2019368654 A AU 2019368654A AU 2019368654 C1 AU2019368654 C1 AU 2019368654C1
Authority
AU
Australia
Prior art keywords
group
alkyl
compound
cmgc
agc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019368654A
Other languages
English (en)
Other versions
AU2019368654A1 (en
AU2019368654B2 (en
Inventor
David Bancroft
Nisit KHANDELWAL
Sebastian Meier-Ewert
Peter Sennhenn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IOmx Therapeutics AG
Original Assignee
IOmx Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IOmx Therapeutics AG filed Critical IOmx Therapeutics AG
Publication of AU2019368654A1 publication Critical patent/AU2019368654A1/en
Application granted granted Critical
Publication of AU2019368654B2 publication Critical patent/AU2019368654B2/en
Publication of AU2019368654C1 publication Critical patent/AU2019368654C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2019368654A 2018-10-23 2019-10-22 Heterocyclic kinase inhibitors and uses thereof Active AU2019368654C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18202164.2A EP3643713B1 (en) 2018-10-23 2018-10-23 Heterocyclic kinase inhibitors and uses thereof
EP18202164.2 2018-10-23
PCT/EP2019/078751 WO2020083926A1 (en) 2018-10-23 2019-10-22 Heterocyclic kinase inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
AU2019368654A1 AU2019368654A1 (en) 2021-05-06
AU2019368654B2 AU2019368654B2 (en) 2025-02-27
AU2019368654C1 true AU2019368654C1 (en) 2025-06-19

Family

ID=64270595

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019368654A Active AU2019368654C1 (en) 2018-10-23 2019-10-22 Heterocyclic kinase inhibitors and uses thereof

Country Status (13)

Country Link
US (3) US12172993B2 (https=)
EP (2) EP3643713B1 (https=)
JP (1) JP7667568B2 (https=)
KR (1) KR20210081353A (https=)
CN (1) CN112955447B (https=)
AU (1) AU2019368654C1 (https=)
BR (1) BR112021007643A2 (https=)
CA (1) CA3116674A1 (https=)
DK (1) DK3643713T3 (https=)
IL (1) IL282588A (https=)
MX (1) MX2021004568A (https=)
SG (1) SG11202103142TA (https=)
WO (1) WO2020083926A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
DK3643713T3 (da) 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
EP3901151B1 (en) * 2020-04-21 2026-04-01 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
CN115398019B (zh) * 2020-08-31 2023-07-07 日本制铁株式会社 钢板及其制造方法
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024539268A (ja) * 2021-10-19 2024-10-28 アイオーエムエックス セラピューティクス アーゲー Ｓｉｋ３阻害剤及びその中間体を調製する合成スキーム及び手順
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
WO2025229127A1 (en) 2024-04-30 2025-11-06 Iomx Therapeutics Ag A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4643861A1 (en) 2024-04-30 2025-11-05 iOmx Therapeutics AG A halogenated-heteroaryl kinase inhbitor for treating soft tissue sarcoma and vascular tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081172A2 (en) * 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008033746A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2018193084A1 (en) * 2017-04-20 2018-10-25 Iomx Therapeutics Ag Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2503715A1 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
ES2377430T3 (es) * 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012040636A2 (en) * 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US9255072B2 (en) 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
NZ702618A (en) * 2012-06-27 2016-12-23 4Sc Discovery Gmbh Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
CN106699744B (zh) 2015-11-18 2021-05-11 四川海思科制药有限公司 一种杂环类酰胺衍生物及其制备方法和在药学上的应用
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor
DK3643713T3 (da) 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
US20230212163A1 (en) 2020-04-21 2023-07-06 Bayer Aktiengesellschaft 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
JP2024539268A (ja) 2021-10-19 2024-10-28 アイオーエムエックス セラピューティクス アーゲー Ｓｉｋ３阻害剤及びその中間体を調製する合成スキーム及び手順

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081172A2 (en) * 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008033746A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2018193084A1 (en) * 2017-04-20 2018-10-25 Iomx Therapeutics Ag Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof

Also Published As

Publication number Publication date
KR20210081353A (ko) 2021-07-01
EP3643713B1 (en) 2025-07-30
DK3643713T3 (da) 2025-11-03
US20210387982A1 (en) 2021-12-16
EP3643713A1 (en) 2020-04-29
WO2020083926A1 (en) 2020-04-30
CN112955447A (zh) 2021-06-11
SG11202103142TA (en) 2021-05-28
AU2019368654A1 (en) 2021-05-06
US20250084076A1 (en) 2025-03-13
EP3870580A1 (en) 2021-09-01
CN112955447B (zh) 2025-09-09
CA3116674A1 (en) 2020-04-30
JP2022505645A (ja) 2022-01-14
MX2021004568A (es) 2021-09-08
IL282588A (en) 2021-06-30
BR112021007643A2 (pt) 2021-07-27
US20250101015A1 (en) 2025-03-27
US12172993B2 (en) 2024-12-24
JP7667568B2 (ja) 2025-04-23
AU2019368654B2 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
AU2019368654C1 (en) Heterocyclic kinase inhibitors and uses thereof
EP3901151B1 (en) Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
US12139480B2 (en) 5-thiazolecarboxamide kinase inhibitor and uses thereof
US20230192701A1 (en) Bicyclic kinase inhibitors and uses thereof
EP2499117B1 (en) A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US8604217B2 (en) Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
IL297483A (en) Bifunctional compounds and their uses
JP2015508085A (ja) フロピリジン誘導体
US20220024944A1 (en) Compounds targeting mutant calreticulin
HK40062784A (en) Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
US20260070914A1 (en) Substituted pyrrolo[2,1-f][1,2,4]triazin-2-amines as cdk2 and cdk4 inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAR 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 07 MAR 2025

FGA Letters patent sealed or granted (standard patent)